Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 05, 2024 03:58 ET | Source: Research and Markets

Global Non-opioid Pain Patches Market 2024-2034 by Patch Type, Distribution Channel and Region - Lidocaine Patches Dominate, Ketoprofen Patches to Register Fastest Growth

Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Global Non-opioid Pain Patches Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.The global...
August 19, 2021 09:00 ET | Source: Sorrento Therapeutics, Inc.

Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives

PALO ALTO, Calif., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), announced that, effective September 1, 2021, ZTlido®...
October 01, 2019 07:00 ET | Source: Scilex Holding Company

Scilex Announces New Medicaid Agreements with CA & FL

PALO ALTO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), is excited to announce that its...
September 30, 2019 07:00 ET | Source: Scilex Holding Company

Scilex Holding Company Strengthens Board of Directors with Appointment of Two Highly Accomplished Pharmaceutical and Biotechnology Executives, Scott Whitcup, M.D. and Elizabeth Czerepak

PALO ALTO, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex) today announced that it appointed Scott M. Whitcup, M.D. as lead independent director to its Board of Directors...
September 23, 2019 07:00 ET | Source: Sorrento Therapeutics, Inc.

Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announced that it has confidentially...
June 05, 2019 07:00 ET | Source: Sorrento Therapeutics, Inc.

Scilex Holding Announces Strong ZTlido Sales Growth After Successful Post-Merger Integration

ZTlido® gross sales grew from approximately $1 million in March to $2.4 million in April and $3.3 million in MaySP-102 pivotal phase 3 trial remains on track for completion in H1 2020ZTlido® 5.4% (3 X...
September 10, 2018 04:00 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido™ Pain Medication

SAN DIEGO, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”) announced today that its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”),...